Case report: ADMIO type 1 linked to de novo STAT3 gain-of-function mutation

Case report context and limits

The only concrete information present in the SOURCE JINA export is the article title: "A case report of ADMIO type 1 caused by a de novo STAT3 gain-of-function mutation," published in Frontiers in Immunology. The rest of the supplied content consists of website navigation, journal section lists, and metadata; the clinical text of the case report itself — including patient history, diagnostics, genetic data, treatment, and outcomes — was not included in the source material provided.

Because the SOURCE JINA body does not contain the article narrative or data, this editorial rewrite is intentionally constrained to what can be reliably reported from the supplied source. No additional clinical facts, numbers, variant annotations, or recommendations have been invented or inferred beyond the title and journal attribution.

Expected case-report sections (not available in source)

A typical case report with this title would normally include the following sections; the SOURCE JINA export did not supply these elements, so they are listed here only as the standard structure clinicians should expect to find when consulting the original article:

• Abstract summarizing presentation, diagnostic approach, and outcome.
• Patient demographics and clinical history.
• Physical examination findings and pertinent positives/negatives.
• Laboratory investigations and imaging studies.
• Genetic testing methodology and results, including the specific STAT3 variant and evidence that it is de novo.
• Functional assays if performed to support a gain-of-function designation.
• Differential diagnosis and rationale for attributing the phenotype to the STAT3 mutation.
• Treatments administered and clinical course, including response and adverse events.
• Discussion placing the case in context of prior literature and mechanistic implications.
• Limitations and conclusions.

None of these anticipated sections or their content were present in the provided source text; therefore their specific findings and data cannot be reproduced here.

Title-derived facts: what is certain from the source

• The article is a case report with the explicit claim in its title that ADMIO type 1 was caused by a de novo STAT3 gain-of-function mutation. This is the only clinical assertion available in the supplied material.

• The article is associated with Frontiers in Immunology according to the source metadata included in the export.

No further details about the case, including how causality was established, the identity of the STAT3 variant, patient age, comorbidities, laboratory or imaging data, functional validation, treatment, or outcome, were present in the SOURCE JINA body.

Missing clinical details and data not reported

The following critical items were not included in the supplied source and therefore could not be summarized or restated from it:

• Patient demographic information (age, sex, ethnicity).
• Clinical presentation and timeline of symptoms.
• Specific diagnostic test results (hematology, immunology, imaging).
• The exact STAT3 nucleotide or amino-acid change and zygosity.
• Evidence presented that the mutation was de novo (parental testing details).
• Functional evidence demonstrating gain-of-function activity (biochemical or cellular assays).
• Management strategy, medications, or interventions used and their outcomes.
• Follow-up duration and long-term status.
• Any reported adverse events or complications.
• Comparative discussion with previously reported cases or series.

Because these elements were not present in the exported source, they are acknowledged as absent rather than restated or inferred.

Implications and recommended next steps for readers

• For clinicians, geneticists, and researchers seeking to evaluate the clinical and scientific validity of the title claim, consult the full article on the Frontiers in Immunology website. The original publication should contain the case narrative, genetic evidence, and any experimental validation required to assess the report.

• When full text access is obtained, critical appraisal should focus on how causality was determined (clinical correlation, segregation, de novo confirmation), the specific STAT3 variant described, and whether functional studies support a gain-of-function designation.

• If the report is being used to inform patient care, verify details directly from the published paper and any supplementary data before applying the information to diagnostics, counseling, or management.

Note: This editorial rewrite preserves only the verifiable information present in the provided SOURCE JINA export. Details that would normally appear in a complete case report were not available in the source and therefore are explicitly not reported here.